319 studies found for:    multiple myeloma | thalidomide
Show Display Options
Rank Status Study
1 Active, not recruiting
Has Results
Lenalidomide and Dexamethasone With or Without Thalidomide in Treating Patients With Multiple Myeloma
Conditions: Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions: Drug: lenalidomide;   Drug: dexamethasone;   Drug: thalidomide;   Other: laboratory biomarker analysis
2 Active, not recruiting Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
Conditions: Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions: Drug: melphalan;   Drug: prednisone;   Drug: thalidomide;   Drug: lenalidomide;   Other: quality-of-life assessment;   Other: laboratory biomarker analysis
3 Active, not recruiting Thalidomide, Dexamethasone, and Clarithromycin in Treating Patients With Multiple Myeloma Previously Treated With Transplant
Conditions: Refractory Multiple Myeloma;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions: Drug: clarithromycin;   Drug: thalidomide;   Drug: dexamethasone
4 Active, not recruiting Cyclophosphamide, Carfilzomib, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Active Multiple Myeloma
Conditions: Multiple Myeloma;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions: Drug: carfilzomib;   Drug: cyclophosphamide;   Drug: thalidomide;   Drug: dexamethasone
5 Completed Arsenic Trioxide and Ascorbic Acid Combined With Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Dietary Supplement: ascorbic acid;   Drug: arsenic trioxide;   Drug: bortezomib;   Drug: dexamethasone;   Drug: thalidomide;   Drug: Aspirin
6 Completed Thalidomide and Prednisone Following Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: prednisone;   Drug: thalidomide
7 Recruiting Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma
Conditions: Extramedullary Plasmacytoma;   Isolated Plasmacytoma of Bone;   Light Chain Deposition Disease;   Primary Systemic Amyloidosis;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions: Drug: dexamethasone;   Drug: cisplatin;   Drug: doxorubicin;   Drug: cyclophosphamide;   Drug: etoposide;   Drug: bortezomib;   Drug: thalidomide;   Drug: melphalan;   Procedure: autologous stem cell transplant
8 Completed Thalidomide Plus Dexamethasone as Maintenance Therapy for Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Thalidomide plus dexamethasone;   Drug: Dexamethasone
9 Completed Bortezomib, Doxorubicin Hydrochloride Liposome, and Dexamethasone Followed by Thalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Multiple Myeloma
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: bortezomib;   Drug: dexamethasone;   Drug: pegylated liposomal doxorubicin hydrochloride;   Drug: thalidomide
10 Unknown  Iberoamerican Protocol With Thalidomide in Patients With Symptomatic Newly Diagnosed Multiple Myeloma Over 65 Years
Condition: Multiple Myeloma
Interventions: Drug: Thalidomide, Cyclophosphamide, Dexamethasone;   Drug: Thalidomide, Dexamethasone;   Drug: Thalidomide, Melphalan, Prednisone
11 Terminated S9922 Combination Chemo Plus Filgrastim With or Without Thalidomide in Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Biological: filgrastim;   Drug: cisplatin;   Drug: cyclophosphamide;   Drug: dexamethasone;   Drug: etoposide;   Drug: thalidomide
12 Active, not recruiting A Study of Combination Thalidomide Plus Dexamethasone Therapy vs. Dexamethasone Therapy Alone in Previously Untreated Subjects With Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: A (Thalidomide + Dexamethasone);   Drug: B (Placebo + Dexamethasone)
13 Active, not recruiting Bortezomib, Thalidomide, and Dexamethasone After Melphalan and Stem Cell Transplant in Treating Patients With Stage I-III Multiple Myeloma
Conditions: Multiple Myeloma and Plasma Cell Neoplasm;   Neurotoxicity
Interventions: Drug: bortezomib;   Drug: dexamethasone;   Drug: melphalan;   Drug: thalidomide;   Genetic: cytogenetic analysis;   Genetic: fluorescence in situ hybridization;   Other: laboratory biomarker analysis;   Other: questionnaire administration;   Procedure: autologous hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation
14 Completed Thalidomide 100 mg/Day Versus Thalidomide 400 mg/Day in Relapse Refractory Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: Thalidomide
15 Completed Thalidomide to Patients With Previously Untreated Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: thalidomide;   Drug: placebo
16 Completed
Has Results
A Study of Thalidomide Plus Dexamethasone (Thal-Dex) Versus DOXIL plusThalidomide Plus Dexamethasone (DOXIL -Thal-Dex) in Patients With Newly Diagnosed Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Thalidomide;   Drug: Dexamethasone;   Drug: DOXIL
17 Completed Thalidomide-Dexamethasone for Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Thalidomide;   Drug: Dexamethasone
18 Active, not recruiting TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy
Condition: Multiple Myeloma
Interventions: Drug: Thalidomide;   Drug: Ara-C;   Drug: BCNU;   Drug: Cisplatin;   Drug: Cytoxan;   Drug: Dexamethasone;   Drug: Doxorubicin;   Drug: Etoposide;   Drug: Filgrastim;   Drug: Recombinant GM-CSF;   Drug: Interferon-alpha-2b;   Drug: Melphalan;   Drug: Vincristine
19 Completed Multiple Myeloma Treated With Thalidomide Before Autotransplant or With Conventional Chemotherapy and as Consolidation/Maintenance Treatment in Young and Elderly Patients : 3 Randomized Studies.
Condition: Multiple Myeloma de Novo Treatment
Interventions: Drug: Thalidomide, Dexamethasone;   Drug: Vincristin , Adriamycin, Dexamethasone = VAD;   Drug: Thalidomide, melphalan, endoxan, dexamethasone (MCDex-Thal);   Drug: melphalan, endoxan, dexamethasone (MCDex)
20 Recruiting Auto-Allo Tandem Stem Cell Transplantation for Patients With Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Procedure: Auto-Allo Tandem SCT and maintenance therapy with Thalidomide/ DLI;   Procedure: auto-auto Tandem stem cell transplantation and maintenance therapy with Thalidomide

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years